Terns Acquires Three Lilly Candidates; Raises $30 Million from Lilly Asia Ventures
publication date: Apr 4, 2018
Terns Pharma, a California-Shanghai startup, in-licensed global rights to three Lilly small molecule candidates aimed at non-alcoholic steatohepatitis (NASH). Terns has its operations in Shanghai and will initially target China approval of the three candidates, with global development to follow. One year ago, Lilly Asia Ventures made an initial $30 million investment in Terns, though the company did not announce the funding until now. Terns focuses on oral, molecularly targeted, small molecule drugs to treat liver disease and cancer. More details....
Stock Symbol: (NYSE: LLY)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.